Therapeutic Area

Nephrology

Therapeutic area intelligence for Nephrology with 5 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Companies

ClinicalJune 21, 2026

A pilot trial is assessing the efficacy of low-dose colchicine in improving vascular disease and biomarkers in CKD stage 3 patients.

ClinicalJune 20, 2026

A clinical trial is evaluating the efficacy of ravulizumab in reducing delayed graft function (DGF) in kidney transplant patients.

ClinicalJune 18, 2026

A clinical trial is underway to evaluate the effects of felzartamab on proteinuria in adults with IgAN.

ClinicalJune 16, 2026

Ultomiris showed a statistically significant reduction of proteinuria in adults with immunoglobulin A nephropathy in the Phase III I CAN trial.

RegulatoryJune 10, 2026

The FDA has accepted a supplemental application for FILSPARI (SPARSENTAN) from TRAVERE.

No catalysts indexed for this entity yet.

Newsletter

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.